Literature DB >> 7865176

The effect of reserpine treatment in vivo upon L-dopa and amphetamine evoked dopamine and DOPAC efflux in vitro from the corpus striatum of male rats.

D E Dluzen1, B Liu.   

Abstract

In the present experiment we tested the effects of L-DOPA and amphetamine upon dopamine and DOPAC efflux in vitro from superfused corpus striatal tissue fragments of male rats who had been pretreated with reserpine. Male rats were treated with reserpine (5 mg/kg) or its vehicle at 24 hours prior to sacrifice and superfusion of the corpus striatum. Two different modes of L-DOPA (5 microM) and amphetamine (10 microM) stimulation, a brief 10-minute and a continuous 60-minute infusion, were tested for their ability to evoke striatal dopamine and DOPAC efflux. Depletion of monoamine storage capacity as achieved with reserpine significantly reduced the amount of basal dopamine and DOPAC released from superfused striatal tissue fragments of male rats. Although basal release rates were significantly reduced, the amount of dopamine and DOPAC released in response to in vitro L-DOPA infusions (10 or 60 minute infusions) was equivalent between reserpine and vehicle treated animals. In contrast, amphetamine stimulated DA release was significantly reduced in male rats treated with reserpine. For both L-DOPA and amphetamine, significantly greater amounts of dopamine were obtained with the 60- versus 10-minute infusion modes. These results demonstrate that the capacity for L-DOPA, but not amphetamine, to evoke dopamine efflux is unaltered under conditions when monoamine storage ability is diminished.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7865176     DOI: 10.1007/bf01271567

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  43 in total

1.  Nanomolar L-dopa facilitates release of dopamine via presynaptic beta-adrenoceptors: comparative studies on the actions in striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mice, an animal model for Parkinson's disease.

Authors:  Y Goshima; Y Misu; N Arai; K Misugi
Journal:  Jpn J Pharmacol       Date:  1991-01

2.  Investigation of dopamine content, synthesis, and release in the rabbit retina in vitro: I. Effects of dopamine precursors, reserpine, amphetamine, and L-DOPA decarboxylase and monoamine oxidase inhibitors.

Authors:  S Ofori; C Bretton; P Hof; M Schorderet
Journal:  J Neurochem       Date:  1986-10       Impact factor: 5.372

Review 3.  How reserpine and chlorpromazine act: the impact of key discoveries on the history of psychopharmacology.

Authors:  G Curzon
Journal:  Trends Pharmacol Sci       Date:  1990-02       Impact factor: 14.819

4.  Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists.

Authors:  T M Engber; Z Susel; J L Juncos; T N Chase
Journal:  Eur J Pharmacol       Date:  1989-09-22       Impact factor: 4.432

Review 5.  The mechanisms of action of L-dopa in Parkinson's disease.

Authors:  O Hornykiewicz
Journal:  Life Sci       Date:  1974-10-01       Impact factor: 5.037

6.  Behavioural role of dopamine D1 receptors in the reserpine-treated mouse.

Authors:  B S Starr; M S Starr; I C Kilpatrick
Journal:  Neuroscience       Date:  1987-07       Impact factor: 3.590

7.  L-dopa esters as potential prodrugs: effect on brain concentration of dopamine metabolites in reserpinized mice.

Authors:  D R Cooper; C Marrel; H van de Waterbeemd; B Testa; P Jenner; C D Marsden
Journal:  J Pharm Pharmacol       Date:  1987-10       Impact factor: 3.765

8.  Tyrosine hydroxylase mRNA concentration in midbrain dopaminergic neurons is differentially regulated by reserpine.

Authors:  G M Pasinetti; D G Morgan; S A Johnson; S L Millar; C E Finch
Journal:  J Neurochem       Date:  1990-11       Impact factor: 5.372

Review 9.  Rationale for continuous dopaminomimetic therapy of Parkinson's disease.

Authors:  T N Chase; F Baronti; G Fabbrini; I J Heuser; J L Juncos; M M Mouradian
Journal:  Neurology       Date:  1989-11       Impact factor: 9.910

10.  Effects of L-dopa and L-tyrosine on release of free and conjugated dopamine, homovanillic acid and dihydroxyphenylacetic acid from slices of rat striatum.

Authors:  G M Tyce; D K Rorie
Journal:  Life Sci       Date:  1985-12-23       Impact factor: 5.037

View more
  2 in total

1.  Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion.

Authors:  Alan L Pehrson; Bita Moghaddam
Journal:  Psychopharmacology (Berl)       Date:  2010-06-29       Impact factor: 4.530

Review 2.  Animal models of Parkinson's disease: a guide to selecting the optimal model for your research.

Authors:  Joana Lama; Yazead Buhidma; Edward J R Fletcher; Susan Duty
Journal:  Neuronal Signal       Date:  2021-12-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.